Fulton Breakefield Broenniman LLC Makes New $409,000 Investment in Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Fulton Breakefield Broenniman LLC acquired a new position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 6,775 shares of the company’s stock, valued at approximately $409,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quest Capital Management Inc. ADV purchased a new stake in Ionis Pharmaceuticals in the third quarter worth about $36,000. Rehmann Capital Advisory Group grew its holdings in shares of Ionis Pharmaceuticals by 41.3% during the second quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after buying an additional 173 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $40,000. Evoke Wealth LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $41,000. Finally, Bradley Foster & Sargent Inc. CT purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $49,000. Institutional investors and hedge funds own 85.64% of the company’s stock.

A number of equities research analysts have recently commented on IONS shares. Needham & Company LLC reiterated a “buy” rating and set a $87.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, December 23rd. Bank of America reiterated a “buy” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, December 31st. William Blair started coverage on shares of Ionis Pharmaceuticals in a report on Thursday, November 14th. They set a “market perform” rating on the stock. Wells Fargo & Co increased their price objective on shares of Ionis Pharmaceuticals from $90.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Finally, BidaskClub upgraded shares of Ionis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $75.67.

In related news, SVP Richard S. Geary sold 5,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $65.06, for a total transaction of $325,300.00. Following the completion of the transaction, the senior vice president now directly owns 26,583 shares of the company’s stock, valued at $1,729,489.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph Klein III sold 812 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $62.90, for a total transaction of $51,074.80. Following the transaction, the director now directly owns 12,683 shares of the company’s stock, valued at $797,760.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,327 shares of company stock valued at $2,534,865. Corporate insiders own 2.40% of the company’s stock.

Shares of NASDAQ IONS opened at $63.40 on Wednesday. The firm has a fifty day moving average price of $62.55 and a 200-day moving average price of $62.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31. The stock has a market cap of $8.94 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 35.97 and a beta of 1.92. Ionis Pharmaceuticals Inc has a 1 year low of $53.34 and a 1 year high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.49. The firm had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.03) earnings per share. On average, research analysts expect that Ionis Pharmaceuticals Inc will post 1.82 EPS for the current year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Recommended Story: Cash Flow

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.